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BACKGROUND. The objective of this study was to update the registry of women in 
the Netherlands with clear cell adenocarcinoma (CCAC) of the cervix or vagina 
with or without intrauterine exposure to diethylstilbestrol (DBS),
METHODS. Ftom a nationwide search in PALGA, the automated pathology registry 
in the Netherlands, data were gathered on women with CCAC born after 1947. 
Information obtained from the clinical files of the patients included reported expo­
sure to DES, patterns of complaints previous to diagnosis, the current status of 
the patients, and the results of cytopathologic examinations previous to histopath­
ologic diagnosis. After review of the histopadiologic slides, the specific pathologic 
characteristics of CCAC were determined. The age distribution of women born 
after 1947 was compared with that of women born before 1947.
RESULTS. Information about possible exposure to DES during pregnancy was avail­
able for 73 of 88 women with CCAC born after 1947. Exposure to DES was reported 
for 47 (64%) of these women. The DES medication was most often reported as 
having started before the 18th week of pregnancy. Cytopathologic examination 
was informative in 81% of the cases of CCAC of the cervix, but only in 41% of the 
cases of CCAC of the vagina. Most patients had Stage I or II tumors at diagnosis. 
Tumor Stage III and IV and a high grade of nuclear atypia were related to unfavor­
able outcome, The age distribution of all patients with CCAC showed two distinct 
peaks: one at young age, [a mean age of 26 years), and one at older age (a mean 
age of 71 years). This bimodal age distribution still applied when the cases in 
which DES exposure was reported had been excluded.
CONCLUSIONS. Despite the fact that DES has not been prescribed to pregnant 
women in the Netherlands in the last 20 years, CCAC is still relevant in our times. 
It is important to stay alert and periodically to update and evaluate the data of 
this registry, including data on women born outside the DES exposure period. The 
bimodal age distribution in this study of women without intrauterine exposure to 
DES suggests a carcinogenesis-promoting role of menarche and menopause and I 
or the existence of a subpopulation with genetic risk factors or exogenous risk 
factors other than exposure to DES. Postmenopausal observation of women ex­
posed to DES must be encouraged for clinical reasons and may help facilitate 
differentiation between these two hypotheses. If these risk factors of CCAC were 
better documented and their interrelationships better defined, CCAC could be­
come an important model of multistep carcinogenesis in tissues sensitive to sex 
hormones. Cancer 1997;79:2229-36. © 1997 American Cancer Society.
KEYWORDS: pathology, diethylstilbestrol (DES), carcinogenesis, hormone.
Since a publication in 1971 by Herbst et al, several studies have linked the occurrence of vaginal clear cell adenocarcinoma (CCAC) 
in young wom en with intrauterine exposure to the synthetic nonste­
roid estrogenic horm one Diethylstilbestrol (DES).1 DES has been pre­
scribed in several countries to pregnant w om en as a preventive ther-
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apy against abortion.2 Based on crude estimates of 
exposure and sales, it has been estimated that in the 
U. S. 1 to 4 million w om en have used DES during preg­
nancy.3 Melnick et al estimated that the chance of 
developing a CCAC is 1 in 1000 for DES-exposed 
women.4 Until 1989, the central American voluntary 
registiy had registered 547 patients with CCAC; in 60% 
of those cases, the mother was reported as having used 
DES during pregnancy,5 However, the absence of cases 
of CCAC in prospective cohort studies, its occurrence 
at an apparently similar rate in Norway (a country in 
which DES was not available6), and biases in the stud­
ies incriminating DES have led other epidemiologists 
to question the relation between DES and CCAC.7 In 
the Netherlands, DES was prescribed from 1947 until 
1975.a Previous publications have examined the occur­
rence of CCAC in the Netherlands.9,10 Until January 1, 
1982 in the Netherlands, 21 patients were known to 
have CCAC.9 Of these, 16 mothers were reported as 
having used DES (76%). In 1991 the results of a study 
of 55 Dutch CCAC patients diagnosed before July 1, 
1988 were published; DES exposure was reported in 
63% of the patients with data on maternal history.10 
The total consumption of DES in the Netherlands can­
not be traced* This can be attributed to the multitude 
of companies distributing DES in the Netherlands; 
moreover, pharmacists work with bulk products rather 
than with individual factory packaging. The Dutch 
DES Action and Information Center has estimated that 
189,000 to 378,000 w om en would have been exposed 
to DES during their mother's pregnancy.8
The objective of the current descriptive study was 
to update, through June 1993, the epidemiologic, clini­
cal, and pathologic data of wom en with CCAC of the 
vagina or cervix. Attention was given to the incidence 
of the tumor, DES exposure, the significance of cytopa- 
thologic examination for the early detection of this 
disease, signs and sym ptom s discovered previous to 
the diagnosis, prognostic parameters, and the age of 
the patients. In addition, the nationwide completeness 
of pathologic records since 1988 in the Netherlands 
also allowed the registration of cases of CCAC in 
women born before 1947, before DES was prescribed 
in the Netherlands.
PATIENTS AND METHODS
For the registry update, an inventory was made of all 
patients with a diagnosis of CCAC of the cervix and/ 
or vagina who were born after 1947. For this purpose, 
a nationwide search was performed in the automated 
pathology archive, PALGA. Since 1988, all Depart­
ments of Pathology in the Netherlands have been con­
nected to the PALGA computer network. The results 
of the nationwide search indicated in which Depart­
ments of Pathology the diagnoses of CCAC of the cer­
vix and/or vagina had been made. The involved de­
partments were asked for a copy of the report of the 
histopathologic examination. If the patient was al­
ready known from a previous evaluation, the new in­
formation was added to the known data. If a patient 
was born after 1947 and had not yet been registered 
at the Central Netherlands Registry (CNR) for CCAC, 
the patient was registered after transfer of a signed 
declaration of approval of scientific research. The CNR 
received declarations from some patients via the 
Dutch DES Action and Information Center, and for 
the remaining patients via their gynecologists.
The relevant histologic slides of the selected pa­
tients were reviewed by two pathologists (A.H. and 
J.B.). If the diagnosis of CCAC was confirmed, a stan­
dard questionnaire requesting the following data was 
sent by the researchers (A.H., M.L., O.S.) to the pa­
tient’s doctors, who were asked to consult their clinical 
files: the year of diagnosis, presence or absence of 
intrauterine DES exposure, reason for DES prescrip­
tion, localization and stage of the tumor, treatment 
for CCAC, patient’s use of contraception, signs and 
symptoms before the diagnosis, and current status of 
the patients. The following data of the patients who 
were already known at the CNR before 1988 were re­
corded: current status, presence of recurrence or m e­
tastasis, supplementary therapy, date of last examina­
tion, and more recent information concerning intra­
uterine DES exposure.
At histopathologic review, the following character­
istics were registered: tumor localization within the 
cervix or vagina, size of the tumor, mitotic activity, 
grade of nuclear atypia, and histologic growth pattern. 
The mitotic activity was defined as the number of mi­
toses per 10 high-power fields (HPF = objective X40), 
The grade of nuclear atypia was determined according 
the criteria of Christopherson et al,11 based on the 
shape and size of the nuclei, the presence and shape 
of nucleoli, and the chromatin pattern. The growth 
pattern of CCAC in this study was classified as: pre­
dominantly tubulocystic, solid, papillary, or mixed. 
Based on the PALGA data of the selected women, the 
results of cytopathologic examination of vagina and/ 
or cervix (performed up to 2 years before the histo­
pathologic diagnosis) were also recorded.
Because DES was not prescribed in the Nether­
lands until 1947,° and until the time of study the CNR 
had focused on DES-associated pathology, no patients 
registered in the CNR had been born before 1947. 
However, for this study cases of patients born before 
1947 who had a diagnosis of CCAC after 1988 could 
be registered because by that time the PALGA was 
completely nationwide.
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RESULTS 
Incidence of CCAC in Women Born after 1947
As a result of the nationwide search in PALGA, it ap­
peared that since the last evaluation of the CNR in 
1988 CCAC had been diagnosed in 27 patients born 
after 1947. One patient from Suriname, who had 
stayed in the Netherlands for 3 m onths for treatment 
of her CCAC, was excluded from the current evalua­
tion. Another seven patients were included, two pa­
tients for whom the CNR did not have all data available 
in 1988, and two new patients who had been reported 
by their gynecologists to the CNR during the current 
evaluation. Histopathologic review of the slides of 
three patients who were not known at PALGA but who 
were known at the DES Action and Information Center 
confirmed the presence of CCAC. Together with the 
55 patients who were known in 1988, the registry as 
of May 1993 included data from 88 w om en with CCAC. 
All tumors of these 88 patients had been diagnosed 
between 1969 and 1993. The highest incidence (ten 
women) occurred in 1988. Thereafter, the incidence 
appeared to decrease, but more time is necessaiy to 
elapse before this can be ascertained. The oldest pa­
tient was born in 1947, and the youngest in 1973. The 
year in which the most women (n = 10) with CCAC 
were born was 1960.
DES Exposure
Maternal information of intrauterine DES exposure 
could be obtained from 73 of 88 patients born after 
1947. This information was obtained from the medical 
records or in some cases from questionnaires returned 
by the gynecologists (n = 64) or the general prac­
titioners (n = 7) of the CCAC patients. In two cases, 
statements of DES exposure were received through 
declarations of the patients themselves to the DES Ac­
tion and Information Center. In 47 of the 73 patients 
with information on maternal history (64%), it was 
stated that they had been exposed to DES. In 20 pa­
tients (27%) no report of exposure to DES was given. 
For 6 patients (8%) it was not known whether the 
mother had used DES during the pregnancy. A reason 
for DES prescription was given in 25 of the 47 w om en  
reported as having been exposed to DES. The most 
frequent reason (n = 15) was that the mother had had 
difficulties in a previous pregnancy, such as abortion 
or threatened abortion and abnormal blood loss.
Of the 47 reportedly DES-exposed patients, the 
majority (29 patients; 62%) had carcinoma of the va­
gina (possibly with extension to the ectocervix, but not 
to the endocervix); 18 (38%) patients had a CCAC of 
the cervix. Of the 20 patients with a negative DES h is­
tory, approximately two-thirds (14 patients; 70%) had  
a CCAC of the cervix.
Data on the point in the pregnancy at which DES 
m edication was reportedly started could be obtained 
from 30 patients. In 21 patients DES was reported as 
having been used before the 18th week, in 8 patients 
it was believed to be prescribed before the 18th week, 
and in 1 patient it was prescribed after the 18th week 
of pregnancy.
Cytologic Examination
Of the group of 88 young patients with CCAC, cytologic 
examination had been performed in 49% (43 patients) 
within 2 years before the histologic diagnosis. Of these 
43 patients, 28 w om en (65%) had a "positive” cyto­
logic diagnosis (“suspected m alignant” or “malig­
nant”) and 15 patients (35%) had a “negative” cyto­
logic diagnosis (“no abnormalities" or “atypia”). The 
percentage of detected carcinomas of the cervix was 
higher than that of the vagina. Twenty-one of the 26 
patients with a cervical carcinoma (81%) and 7 of the
17 patients with a CCAC of the vagina (41%) had a 
“positive" cytologic diagnosis.
Signs and Symptoms
Of the 88 patients born after 1947, 57 had reported 
vaginal blood loss before the diagnosis of CCAC was 
made. Eleven patients reported dyspareunia. Seven 
patients (8%) had their CCAC diagnosed during a regu­
lar examination because of known intrauterine DES 
exposure. In 6 patients (7%) no symptoms were m en­
tioned. The duration of the symptoms was <  6 months 
in 42 patients and >  6 m onths in 30 patients. There 
was no clear relation betw een the duration of symp­
tom s and mortality of CCAC.
Clinical Status
Of the 88 w om en with CCAC of the vagina or cervix,
18 (20%) had died of disease before May 1, 1993. Nine 
patients who had died of the tumor had a CCAC of 
the cervix and nine a CCAC of the vagina. Eight of the 
12 dead patients (67%) with known maternal history of 
DES exposure had been exposed to DES. All 18 patients 
died within 5 years of the initial diagnosis (range, 1 1 -  
53 months). Nine of the 18 dead patients had re­
maining tumor since the initial diagnosis; three had 
metastases. The remaining nine patients had devel­
oped a local recurrence and/or m etastases. The metas- 
tases were usually pulmonary or in the lymph nodes 
(inguinal, paraaortic, and supraclavicular). All local re­
currences had been diagnosed within 3 years after the 
initial diagnosis (range, 5 -3 0  months). At last follow- 
up, 61 patients were alive without signs of tumor. Two 
of these patients were without any signs of malignancy 
after surgical treatment for a local recurrence (follow- 
up periods after treatment of the recurrence were 51
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TABLE 1
Relation between Clinical Status of the Patients and Tumor Stage
Stage Total DOD ^  5 survivors >  5 survivors
Status
unknown
I 36 (100%) 4 (11%) 11 (31%) 20 (56%) 1 (3%)
II 41 (100%) 9 (22%) 6 (15%) 25 (61%) 1 (2%)
III fi (100%) 2 (33%) 0 4 (67%) 0 (0%)
IV 4 (100%) 3 (75%) 0 0 1 (25%)
Total 87 18 17 49 3
DQD: dead of disease; >  5 survivors: patients alive >  5 years after initial diagnosis; <  5 survivors; patients alive with a follow-up of <  5 years.
months and 62 months, respectively), and 1 patient patients had an unfavorable prognosis and 19 had a
was alive without signs of malignancy after treatment favorable prognosis. In the current study follow-up
of a local recurrence in 1978 and treatment of a solitary was not available for 1 of these 19 patients with a
metastasis in the left lung hilus in 1980. Three patients favorable prognosis. At last follow-up, the remaining
were alive with recurrence or metastasis (range of fol- 18 patients were still alive after the diagnosis. Two
low-up period, 12-48 months), and 2 patients were patients were alive with a local recurrence, one patient
alive without complete follow-up data. No follow-up was alive with lung metastasis, and two patients were
data were available for four patients.
Tumor Characteristics and Prognostic Parameters
Using the criteria of the International Federation of 
Gynecology and Obstetrics,12 41 tumors (47%) were 
classified as CCAC of the vagina and 47 (53%) as CGAG 
of the cervix. If the tumor involved the anatomic en- 
docervix but had a predominantly vaginal localization, 
it was still considered to be a CCAC of the ceivix. The
tumor was localized in the upper one-third of the va- Age Distribution of CCAC Patients Born after 1947
alive without signs of malignancy after treatment for 
local recurrence. Of the two patients with an unfavor­
able prognosis (1% and 36%, respectively, chance of 
surviving >  5 years), the first patient with CCAC of the 
vagina (NA = 3, STA = IV) died 26 months after the 
initial diagnosis. The other patient with CCAC of the 
vagina (NA3, STA2) was still alive >  5 years after the 
initial diagnosis without signs of malignancy.
gina and/or cervix in 74 patients. Tables 1 and 2 show  
the relation between clinical status and tumor charac-
The age at diagnosis of the 88 CCAC patients born 
after 1947 is shown in Figure 1. The youngest patient
teristics. The percentage of patients who died corre- was age 8 years and the oldest 37 years. The mean age
lated with higher stages (Table 1). There was no clear was 23.6 years. The age of DES-exposed woman ranged
difference in tumor stage between patients with or from 14 years to 37 years with a mean age of 21.3
without DES exposure. No data on survival were years. The youngest patient who had not been exposed
known for three patients. For two patients, a complete to DES was age 18 years at diagnosis and the oldest
revision of the histologic slides was not possible. Ta- was age 37 years. The mean age in this patient group
bles 1 and 2 show that the following characteristics was 26.1 years, 
coincided with an unfavorable outcome: Stage III or
IV, a tumor of >  40 mm in greatest dimension, a solid Age Distribution of All CCAC Patients (Including Those
histologic growth pattern, a high number of mitoses Born before 1947)
( > 1 0  per 10 HPF), and Grade 3 nuclear atypia. In an Figure 2 shows the age distribution of 64 patients diag-
earlier report by the CNR, a classification criterion had nosed with CCAC between 1988 and 1993, regardless of
been m entioned for the prediction of disease outcome the year of birth (before or after 1947). The figure shows
in CCAC patients that was based on grade of nuclear 
atypia (NA) and tumor stage (STA).10 The group of
two clearly separated prominent peaks. The first peak 
contains data of 30 young women with ages ranging
patients known to be alive was divided into 2 sub- from 17 to 37 years; the mean age was 26 years. The
groups: patients alive >  5 years after the diagnosis ("> second peak contains data from 34 older women (all
5 survivors'’) and those who were alive with a follow- born before 1947) and ranges in age from 44 to 88 years;
up period of <  5 years ("< 5 survivors”). The subgroup the mean age was 71 years. The first peak includes all
of <  5 survivors was comprised of 21 patients. On the DES daughters. In Figure 3, the ages of the same group
basis of the classification criterion of 1988, 2 of these of women are shown, excluding women with a positive
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TABLE 2
Several Histopathologic Parameters in Relation to Clinical Status of the Patient
Total DOD ^  5 survivors >  5 survivors
Lost to 
follow-up
Tumor size 
(mm)
< 4 0 51 (100%) 4 (8%) 12 (24%) 34 (67%) 1 (2%)
> 4 0 27 (100%) 12 (44%) 4 (15%) 9 (33%) 2(7%)
Unknown 10 (100%) 1 (20%) 1 (10%) 6 (60%) 1 (10%)
Growth pattern
Tubulo cystic 51 (100%) 6 (12%) 11 (22%) 33 (65%) 1 (2%)
Solid 16 (100%) 7 (44%) 1 (6%) 6 (38%) 2 (13%)
Papillary 2 (100%) 1 (50%) ------- 1 (50%) -------
Mixed 17 (100%) 4 (24%) 4 (24%) 8 (47%) 1(6%)
Unknown 2 (100%) ------- 1 (50%) 1 (50%) -------
Mitoses/10 HPF
< 10 58 (100%) 7 (12%) 12 (21%) 36 (62%) 3 (5%)
> 10 24 (100%) 10 (42%) 3 (13%) 10 (42%) 1 (4%)
Unknown 6 (100%) 1 (17%) 2 (33%) 3 (50%) —
Nuclear atypia
Grade 1 5 (100%) 1 (20%) ------- 4 (80%) —
Grade 2 47 (100%) 3 (6%) 14 (30%) 26 (55%) 4 (9%)
Grade 3 30 (100%) 13 (43%) 2 (7%) 15 (50%) —
Unknown 6 (100%) 1 (17%) 1 (17%) 4 (67%) —
Total 88 18 17 49 4
DOD: dead of disease; HPF: high-power fields.
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FIGURE 1. Age at diagnosis of CCAC patients born after 1947 (n =  88). 
CCAC: clear cell adenocarcinoma.
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FIGURE 2. Age distribution of all patients with clear cell adenocarcinoma 
(CCAC) diagnosed since 1988, regardless of whether they were born before 
or after 1947 (n =  64).
DES history. In Figure 4, the women with an uncertain 
DES history (n = 5) are excluded. These figures also 
show a bimodal distribution; a peak is visible at young 
age. No transformation allows the distribution to be nor­
mal, and it contains two populations by maximal likeli­
hood statistical analysis. Approximately two-thirds of the 
34 older women had CCAC of the cervix (22 patients)
and one-third had CCAC of the vagina (12 patients). The 
same ratio applied for the younger women who had 
not been exposed to DES or whose DES histoiy was 
unknown. Two-thirds of the young women who had 
been exposed to DES had a CCAC of the vagina (11 
patients), and one-third of the patients had CCAC of the 
cervix (5 patients).
2234 CANCER June 1,1997 / Volume 79 /  Number 11
Number of CCAC patients
0 10 20 30 40 50 60 70 80 90 100 
Age in years
FIGURE 3. Age of all patients with clear cell adenocarcinoma (CCAC) 
diagnosed since 1988, excluding women reported as having been exposed 
to diethylstilbestrol (n =  48),
Number of CCAC patients
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FIGURE 4. Age of the patients with clear cell adenocarcinoma (CCAC) 
diagnosed since 1988, as in Figure 3, but excluding those patients with 
an uncertain history of diethylstilbestrol exposure (n =  43).
DISCUSSION
In this overview the epidemiologic, clinical, and histo­
pathologic characteristics have been described in a 
group of 88 Dutch women born after January 1947 
with a CCAC of the cervix or vagina diagnosed before 
May 1993. The increase in the number of young 
wom en diagnosed with CCAC since 1970 that has been  
described in the American literature1 appears also to 
have taken place in the Netherlands. However, one 
cannot be certain of this in the U.S., because the Amer­
ican registry has remained on a voluntary basis. Even 
when the registry was population-based, as in the state 
of Connecticut, it appeared that half of the CCAC cases 
had not been diagnosed as such.13 A fortiori, underdi­
agnosis can be suspected in cases diagnosed before 
1971. Also in the Netherlands, previous and possibly 
even recent underdiagnosis remains possible because 
PALGA includes only all patients diagnosed since 1988 
and because it cannot be excluded that some CCACs 
are hidden under the diagnosis of “adenocarcinoma'-' 
or "carcinoma.” Given the notoriety of a DES-CCAC 
relationship, it is quite possible that cases without re­
ported exposure to DES have failed to be diagnosed 
as CCAC, but this could be ascertained only by a dedi­
cated study of all vaginal and cervical tumors. From 
the current registry data, it appears that in 1988 the 
highest number of patients with CCAC were diagnosed 
and that the incidence appeared to decrease thereaf­
ter. The highest incidence in the U. S. was observed in 
1975.5 The recent higher incidence in the Netherlands 
corresponds with a later birth peak of the DES-exposed 
Dutch patients.10 It also is possible that the different 
setup of the registry in the U.S., based on a voluntary 
entry, and the possibility of previous under diagnosis, 
have contributed to the differences between the data 
in the U.S. and the Netherlands.
In the current Dutch registry, 47 of the 73 women 
with data on maternal histoiy (64%) had, according to 
the authors' information, been exposed to DES. This 
percentage is comparable to that of the previous 
Dutch report on data until 1988 (63%), the registry of 
the U. S. in 1989 (60%), and two French series.5,10*14,15 
In the current study, 99% of women whose physician 
had information concerning the time of DES exposure 
had been exposed to DES before the 18th week of 
pregnancy. The most frequent reasons for DES being 
prescribed to the patients’ mothers were problems in 
previous pregnancies, such as abortion or threatened 
abortion and abnormal blood loss.
The results of the cytologic examination showed 
a diagnosis of “malignant" or "suspected malignant” 
disease in 81% of the patients with cervical carcinoma 
and in 41% of patients with vaginal carcinoma. These 
results are similar to previous findings of the CNR in 
1988.10 Only cervical smears and no vaginal smears 
had been taken in those cases of CCAC of the vagina 
that had a cytologic diagnosis of "no abnormalities” 
or “atypia.” This supports earlier observations that 
cytologic examination can make an important contri­
bution to the diagnosis of CCAC if the smear-taking 
procedure is performed well, i.e., is comprised of sepa­
rate smears from the cervix and from the four quad­
rants of the vagina.
Comparing the current findings with previous reg­
istry analysis, it appears that patients are increasingly 
being diagnosed at an earlier stage and after a shorter 
time interval between report of symptoms and diagno­
sis.9,10 The patients who have been diagnosed since
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1988 more often had a Stage I tumor (59%) than the 
patients who were entered in the registry before 1988 
(31%). Since 1988, more patients (82%) had reported 
no symptoms at diagnosis, or reported symptoms of
< 6 months' duration, than before 1988 (53%). This 
suggests that secondary prevention measures were 
successful.
Important parameters for th e  determination of 
prognosis of CCAC patients are stage, tumor size, 
growth pattern, nuclear atypia, and mitotic activ- 
ity 5,10,16,17 jn ^  current study, an unfavorable progno-
sis corresponded with high stage, large tumor size, 
high grade of nuclear atypia, and high mitotic activity. 
The tubulocystic growth pattern corresponded with a 
better prognosis than the solid or mixed growth pat­
tern. A classification criterion for the prediction of 
prognosis from the CNR in 1988 that was based on  
stage and nuclear atypia appeared in a follow-up study 
to correctly classify 95% of the patients.
It has been m entioned in the American literature 
that CCAC of the vagina and cervix may occur at an 
older age, but this has attracted little attention since 
then.18 In a study by Kaminski and Maier from 1983, 
data were reported from 23 w om en with CCAC of the 
cervix who had not been exposed to DES, and who 
varied in age from 13 to 80 years.19. In the current 
study the authors examined the occurrence of CCAC 
of the vagina or cervix diagnosed between 1988 and 
1993 in the whole population, regardless of the w om ­
en's age and history of DES exposure. The age distribu­
tion of the 64 patients with CCAC who were diagnosed 
since 1988 showed 2 clearly separated peaks. The first 
contained 30 young wom en with a mean age of 26 
years. The second contained 34 older wom en born 
before 1947, who had thus not been exposed to DES, 
with a mean age of 71 years. The first peak contained  
all DES daughters. If the DES daughters were excluded, 
the age distribution still showed a bimodal pattern, 
with a first peak at age 2 5 -3 0  years. Such bimodal age 
distributions have been described for those types of 
cancer in which an important genetic factor has been  
determined (e.g., retinoblastoma, medullary carci­
noma of the thyroid, and carcinoma of the colon).20 
Hereditary cases of carcinoma of the breast and ovary 
are strongly concentrated in the younger age group.21
The authors' finding of a clearly bimodal age dis­
tribution in women with CCAC has not been described 
previously. In the hypothesis that a population at risk 
exists, the bimodal age distribution is characteristic 
for the existence of a subpopulation with a strongly 
increased risk. DES exposure, which is thus far, to the 
authors’ knowledge, the only researched risk factor, 
appears to be a risk factor, but does not provide an 
explanation for the prominent peak at a young age in
w om en not exposed to DES. The maximum risks for 
non-DES-related CCAC thus occur at the ages of ap­
proximately 25 and 70 years, respectively. At least two 
explanations are possible: a risk period or a risk popu­
lation.
Risk period
An in terval o f  10 to  20 years  after menarche and m eno­
pause is in agreement with the estimated evolution 
time between the malignant transformation of the first 
cell and the diagnosis of several types of cancer such as 
carcinoma of the cervix.22 The carcinogenic risk would 
thus strongly increase after the significant changes in 
the hormonal climate with the rise of the pituitary 
gonadotropin hormones, luteinizing hormone and fol­
licle-stimulating hormone, that mark the menarche 
and m enopause. The effects of this "hormone storm” 
could play a causal role. This hypothesis does not im ­
pact on the distribution of the risk within the popula­
tion, and it is compatible with a low and homogeneous 
distributed risk, as well as with the existence of a sub­
population with a genetically or otherwise defined 
higher sensitivity for changes in the gonadotropin cli­
mate. Thus, in utero DES exposure would in both cases 
only increase an already existing risk of carcinogene­
sis. It is of clinical importance that this hypothesis 
would predict an increased incidence of CCAC in post­
m enopausal DES exposed wom en. Continued surveil­
lance of these w om en after the age of 40 years would 
be warranted.
Risk population
Changes in the gonadotropin climate do not play a 
role in this hypothesis. The age peaks reflect two popu­
lations with a significantly different risk of CCAC. The 
highest number of w om en with a normal and low risk 
have a peak at older age, as is the case with most 
tumors whose incidence rate increases with age due 
to cumulative risks. The peak at a younger age must 
then be explained by a subpopulation with increased 
risk. This risk is either constitutional (genetic or other­
wise), is based on exposure to exogenous agents other 
than DES, or a com bination of the two (e.g., a constitu­
tional sensitivity for carcinogens). In this hypothesis, 
DES could also increase an existing risk to develop 
CCAC at a young age. However, no increased inci­
dence of CCAC is then expected in postmenopausal 
DES-exposed wom en.
Thus in both the risk period and the risk popula­
tion hypotheses, factors other than DES also appear 
to play a role in the acceleration of carcinogenesis in 
the group of younger patients. These may be other 
exogenous or genetic risk factors.
Recently a familial chrom osom e translocation has
2236 CANCER June 1,1997 /  Volume 79 /  Number 11
been described in chromosomes 3 and 6 
{46,XX,t(3;6)(q29;q23)} in both a mother and her DES- 
exposed daughter.23 The combination of the use of 
DES by the mother and the presence of a familial chro­
mosome translocation in both herself and her daugh­
ter may, according to Leschot, occur frequently.23 
Elaborating on this, it may be possible that some of 
the chromosomal changes that occur in some women 
with multiple miscarriages m aybe linked to a potential 
for neoplastic transformation. A relationship between 
repeated spontaneous abortion, breast carcinoma, 
and an estrogen receptor gene variant has been de­
scribed.24,25 If a hypothesis concerning genetic factors 
for the occurrence of CCAC is supported, then the 
initiating neoplastic potential of DES should be recon­
sidered. Further research in this respect is necessary. 
Concentrating on DES as the only risk factor for CCAC 
may stand in the way of gaining increased knowledge 
of hormonal carcinogenesis.
Although DES has not been prescribed to women 
during pregnancy in the Netherlands for almost 20 
years, the problems related to intrauterine DES expo­
sure are still relevant. It is important to remain alert 
and to periodically update and evaluate the data of 
this registry, and to keep an open mind regarding the 
existence of additional or alternative risk factors.26
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